Hence, CDK4 T172-phosphorylation might be the most relevant biomarker of potential tumor sensitivity to CDK4/6i, by identifying or predicting the presence of active CDK4, which is the actual target of inhibitory drugs. Here, CDK4 is linked to neoplasm.